Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression

被引：7

作者：

Friedes, Cole ^{[1
]}

Yegya-Raman, Nikhil ^{[1
]}

Zhang, Siqi ^{[2
]}

Iocolano, Michelle ^{[1
]}

Cohen, Roger B. ^{[3
]}

Aggarwal, Charu ^{[3
]}

Thompson, Jeffrey C. ^{[4
]}

Marmarelis, Melina E. ^{[3
]}

Levin, William P. ^{[1
]}

Cengel, Keith A. ^{[1
]}

Ciunci, Christine A. ^{[3
]}

Singh, Aditi P. ^{[3
]}

D'Avella, Christopher ^{[3
]}

Davis, Christiana W. ^{[3
]}

Langer, Corey J. ^{[3
]}

Feigenberg, Steven J. ^{[1
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[2] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA

[3] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA

来源：

CLINICAL LUNG CANCER | 2024年 / 25卷 / 01期

关键词：

Oligoprogression; LCT; Pembrolizumab; SBRT; NSCLC; TYROSINE KINASE INHIBITORS; LUNG-CANCER; RADIATION-THERAPY; DISEASE; EVOLUTION;

D O I：

10.1016/j.cllc.2023.09.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The patterns of failure and frequency of oligoprogression for mNSCLC on first-line immunotherapy is not well studied. Oligoprogression occurred in 39.9% of all cases and most disease failure occurred in known sites of tumor. Oligoprogression (vs. polyprogression) and the use of radiotherapy (vs. changing systemic therapies) to treat oligoprogression was associated with improved survival. In mNSCLC treated with immunotherapy, oligoprogression is relatively frequent but randomized data are needed to describe the benefits of local therapy in this population. Introduction: The patterns of failure (POF) for metastatic non-small-cell lung cancer (mNSCLC) treated with immunotherapy are not well established. Methods: We conducted a retrospective cohort study of mNSCLC that received first-line pembrolizumab with or without chemotherapy at a single academic center from 2015 to 2021. We defined POF with 2 classifications: 1) local, regional, or distant failure, or 2) failure in existing lesions, new lesions, or a combination. Oligoprogression was defined as disease progression (PD) in <= 3 sites of failure. Overall survival (OS) was measured via Kaplan-Meier and modelled with Cox regression. Results: Of 298 patients identified, 198 had PD. Using POF classification 1, most failures were distant (43.9%) or a combination of locoregional and distant (34.4%). For POF classification 2, failures occurred in a combination of new and existing lesions (45.0%), existing lesions alone (33.3%), or in new lesions only (21.7%). Oligoprogression occurred in 39.9% (n = 79) cases. Median OS was higher in the following: PD in existing lesions vs. new or new + existing lesions (28.7 vs. 20.2 vs. 13.9 months, P < .001) and oligoprogression vs. polyprogression (35.1 vs. 12.2 months, P < .001). In oligoprogression, median OS was better for those who received radiation to all sites of PD (62.2 months) than for those who changed systemic therapy (22.9 months, P = .007). On multivariable analysis, radiation for oligoprogression (HR 0.35, 95% CI: 0.20-0.62, P < .001) was associated with improved OS. Conclusions: In mNSCLC treated with pembrolizumab, oligoprogression is relatively common. Randomized data are needed to define the benefits of radiation in oligoprogressive mNSCLC.

引用

页码：50 / 60.e6

页数：17

共 28 条

[1] Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy [J].

Al-Halabi, Hani ;

Sayegh, Karl ;

Digamurthy, Subba R. ;

Niemierko, Andrzej ;

Piotrowska, Zofia ;

Willers, Henning ;

Sequist, Lecia V. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) :1601-1607

[2] Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors [J].

Chai, Rong ;

Yin, Yipengchen ;

Cai, Xuwei ;

Fu, Xiaolong ;

Zhang, Qin .

FRONTIERS IN ONCOLOGY, 2021, 11

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy [J].

Friedes, Cole ;

Mai, Nicholas ;

Fu, Wei ;

Hu, Chen ;

Hazell, Sarah Z. ;

Han, Peijin ;

McNutt, Todd R. ;

Forde, Patrick M. ;

Redmond, Kristin J. ;

Voong, K. Ranh ;

Hales, Russell K. .

CANCER, 2020, 126 (20) :4572-4583

[5] Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib [J].

Gan, Gregory N. ;

Weickhardt, Andrew J. ;

Scheier, Benjamin ;

Doebele, Robert C. ;

Gaspar, Laurie E. ;

Kavanagh, Brian D. ;

Camidge, D. Ross .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04) :892-898

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].

Gerlinger, Marco ;

Rowan, Andrew J. ;

Horswell, Stuart ;

Larkin, James ;

Endesfelder, David ;

Gronroos, Eva ;

Martinez, Pierre ;

Matthews, Nicholas ;

Stewart, Aengus ;

Tarpey, Patrick ;

Varela, Ignacio ;

Phillimore, Benjamin ;

Begum, Sharmin ;

McDonald, Neil Q. ;

Butler, Adam ;

Jones, David ;

Raine, Keiran ;

Latimer, Calli ;

Santos, Claudio R. ;

Nohadani, Mahrokh ;

Eklund, Aron C. ;

Spencer-Dene, Bradley ;

Clark, Graham ;

Pickering, Lisa ;

Stamp, Gordon ;

Gore, Martin ;

Szallasi, Zoltan ;

Downward, Julian ;

Futreal, P. Andrew ;

Swanton, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892

[8] Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation [J].

Guckenberger, Matthias ;

Lievens, Yolande ;

Bouma, Angelique B. ;

Collette, Laurence ;

Dekker, Andre ;

deSouza, Nandita M. ;

Dingemans, Anne-Marie C. ;

Fournier, Beatrice ;

Hurkmans, Coen ;

Lecouvet, Frederic E. ;

Meattini, Icro ;

Romero, Alejandra Mendez ;

Ricardi, Umberto ;

Russell, Nicola S. ;

Schanne, Daniel H. ;

Scorsetti, Marta ;

Tombal, Bertrand ;

Verellen, Dirk ;

Verfaillie, Christine ;

Ost, Piet .

LANCET ONCOLOGY, 2020, 21 (01) :E18-E28

[9] OLIGOMETASTASES [J].

HELLMAN, S ;

WEICHSELBAUM, RR .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :8-10

[10] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

← 1 2 3 →